LENSAR Reports Q2 2024 Results with 17 ALLY Placements and Terminates Oertli Development Agreement

LENSAR, Inc.

2024-Q2 EPS reported -$0.98 revenue$23,224,000

Q2 2024 revenue $12.6M, up 5% YoY; net loss $9.0M vs $8.8M loss in Q2 2023.
Placed 17 ALLY Systems in Q2 2024, highest since launch; total installed base ~330 systems.
Worldwide procedure volume increased 19% to 42,203 in Q2 2024 from 35,349 in Q2 2023.
Terminated Development Agreement with Oertli Instrumente AG effective Aug 5, 2024, with no termination penalties.
Received MDR certification (CE Mark) and Taiwan FDA approval; first EU and SE Asia ALLY systems shipped.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.